Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
Main Authors: | Taylor, P, Elboudwarej, E, Li, W, Hawtin, R, Liu, J, Mirza, A |
---|---|
Format: | Conference item |
Published: |
BMJ Publishing Group
2019
|
Similar Items
-
Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-severely Active Rheumatoid Arthritis (FINCH3)
by: Taylor, P, et al.
Published: (2020) -
Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
by: Taylor, P, et al.
Published: (2020) -
Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019) -
Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotinib in MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3)
by: Taylor, PC, et al.
Published: (2020) -
Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotnib in adults with moderately-to-severely active rheumatoid arthritis with prior inadequate response to methotrexate (FINCH1)
by: Taylor, PC, et al.
Published: (2020)